Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:NVUS Novus Therapeutics (NVUS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrends About Novus Therapeutics Stock (NASDAQ:NVUS) 30 days 90 days 365 days Advanced Chart Ad Porter & CompanyWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Novus Therapeutics alerts:Sign Up Key Stats Today's Range$3.16▼$3.6550-Day Range$9.85▼$16.5052-Week Range$4.50▼$27.32Volume248,339 shsAverage Volume78,851 shsMarket Capitalization$5.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNovus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Receive NVUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NVUS Stock News HeadlinesCAMP4 Therapeutics Corp.October 23 at 4:18 AM | money.usnews.comTango Therapeutics Share Price (TNGX.US)September 3, 2024 | lse.co.ukWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)Sarepta Therapeutics Share Price (SRPT.US)July 21, 2024 | lse.co.ukVivoryon Therapeutics NV VVYMarch 1, 2024 | morningstar.comViking Therapeutics IncFebruary 22, 2024 | money.usnews.comCYT Cyteir Therapeutics, Inc.December 28, 2023 | seekingalpha.comNovo Holdings invests in US$105 million Series C Funding of Alentis TherapeuticsMay 11, 2023 | finance.yahoo.comSee More Headlines NVUS Stock Analysis - Frequently Asked Questions How were Novus Therapeutics' earnings last quarter? Novus Therapeutics, Inc. (NASDAQ:NVUS) released its quarterly earnings results on Monday, November, 16th. The biopharmaceutical company reported ($5.51) EPS for the quarter, missing the consensus estimate of ($1.64) by $3.87. Read the conference call transcript. When did Novus Therapeutics' stock split? Novus Therapeutics's stock reverse split before market open on Monday, October 5th 2020. The 1-18 reverse split was announced on Friday, October 2nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 2nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. What other stocks do shareholders of Novus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novus Therapeutics investors own include SCYNEXIS (SCYX), CymaBay Therapeutics (CBAY), Sorrento Therapeutics (SRNE), Bristol-Myers Squibb (BMY), Miragen Therapeutics (MGEN), Selecta Biosciences (SELB) and Tonix Pharmaceuticals (TNXP). Company Calendar Last Earnings11/16/2020Today10/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:NVUS CUSIPN/A CIK1404281 Webnovustherapeutics.com Phone949-238-8090FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($21.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-133.49% Return on Assets-30.52% Debt Debt-to-Equity RatioN/A Current Ratio18.78 Quick Ratio18.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.13 per share Price / Book0.27Miscellaneous Outstanding Shares1,436,000Free FloatN/AMarket Cap$5.01 million OptionableNot Optionable Beta2.07 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:NVUS) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.